Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ:ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant and/or traceable to the Company’s initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or between September 18, 2020 and June 17, 2021 (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ATHA.
There is no cost or obligation to you.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.
The lawsuits allege that defendants issued materially false and misleading information and failed to disclose: (1) that CEO Dr. Leen Kawas had published research papers containing improperly altered images while she was a graduate student; (2) that this purported research was foundational to Athira’s efforts to develop treatments for Alzheimer’s because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer’s; (3) that, as a result, Athira’s intellectual property and product development for the treatment of Alzheimer’s were based on invalid research; and (4) that, as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
On June 18, 2021, Athira shares plummeted 39% to $11.15, well below the $17.00 IPO price, after the Company disclosed that its Board decided to place Chief Executive Kawas on leave pending a review of actions stemming from research Dr. Kawas conducted while at Washington State University.
Athira Pharma, Inc.
* The submission of this form does not create an attorney-client relationship.
Filed on 06/28/2021
Lead Plaintiff Deadline 08/24/2021
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
James M. Wilson, Jr. email@example.com Phone (212) 983-9330 Fax (212) 983-9331
Robert W. Killorin firstname.lastname@example.org Phone (404) 847-0617 Fax (404) 506-9534